Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
323.3 AUD | -0.91% | -1.40% | +8.26% |
May. 29 | UK’s Competition Regulator Closes Cochlear-Demant Deal | MT |
May. 21 | Cochlear Completes Acquisition of Oticon Medical's Cochlear Implant Business | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With an expected P/E ratio at 55.57 and 49.56 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Most analysts recommend that the stock should be sold or reduced.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.26% | 14.37B | B | ||
+4.99% | 19.07B | A | ||
+10.34% | 10.23B | B- | ||
-20.13% | 1.97B | - | ||
-5.28% | 1.67B | B+ | ||
+7.52% | 1.34B | D- | ||
+1.63% | 542M | - | ||
0.00% | 395M | - | - | |
+65.38% | 187M | - | ||
+25.30% | 103M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- COH Stock
- Ratings Cochlear Limited